Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Extensive clinical experience has shown that systemic interleukin (IL)-2 administration can induce complete or partial regression of renal cell cancer (RCC) metastases in 15 to 20 % of patients. Since IL-2 has no direct anti-cancer effects, it is believed that cancer regression is mediated either by a direct modulation of immune cell effector functions or through the mediation of soluble factors released as a result of IL-2 administration.We previously observed that transcriptional and protein changes induced by systemic IL-2 administration affect predominantly mononuclear phagocytes with little effect, particularly within the tumor microenvironment, on T cell activation, localization and proliferation. It further appeared that mononuclear phagocyte activation could be best explained by the indirect mediation of a secondary release of cytokines by IL-2 responsive cells either in the circulation or in peripheral tissues.To better characterize the cytokine outburst that follows systemic IL-2 administration we followed the serum levels of 68 soluble factors in ten patients with RCC undergoing high dose (720,000 IU/kg intravenously every 8 hours) IL-2 therapy. Serum was collected before therapy, 3 hours after the 1st and 4th dose and assayed on a multiplexed protein array platform. This study demonstrated that 1) the serum concentration of more than half the soluble factors studied changed significantly during therapy; 2) changes became more dramatic with increasing doses; 3) subclasses of soluble factors displayed different kinetics and 4) cytokine patterns varied quantitatively among patients.This study shows that the cytokine storm that follows systemic IL-2 administration is complex and far-reaching inclusive of soluble factors with disparate, partly redundant and partly contrasting effects on immune function. Therefore comparing in parallel large number of soluble factors, it sets a comprehensive foundation for further elucidation of "cytokine storm" in larger patient pools. Based on this analysis, we propose a prospective collection of serum samples in a larger cohort of patients undergoing IL-2 administration with the purpose of discerning patterns predictive of clinical outcome and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cytokines such as IL-2 and IL-12 were previously introduced to increase intratumoral lymphocyte infiltration and anti-tumor immunity; however, these treatments were associated with severe toxicity”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Panelli et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184 · cited 3×
“Hierarchical clustering [21] was applied to the data set encompassing 46 cytokines significantly expressed (excluding IL-2) between before and after 4 doses of IL-2 across 10 serum samples (P2,3,4,5,9,12,13,14,15,16) obtained before, after 1 and after 4 doses of IL-2 (720,000 IU/kg).”
MethodInfluentialSimultaneous Statistical Inference
Miller, R. G. (1981) · Springer Series in Statistics · doi:10.1007/978-1-4613-8122-8 · Cited by 5,604
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088 · cited 2×
“Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines.”
MethodAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationHigh-fidelity mRNA amplification for gene profiling
Wang, E., Miller, L. D., Ohnmacht, G. A., Liu, E. T., & Marincola, F. M. (2000) · Nature Biotechnology · doi:10.1038/74546 · Cited by 675 · cited 1×
“Samples were serially obtained through blood draws and fine needle aspirates of melanoma metastases following a previously validated RNA amplification procedure [13].”
MethodSelf-citationCirculating Cell Adhesion Molecules and Death in Patients With Coronary Artery Disease
Blankenberg, S., Rupprecht, H. J., Bickel, C., Peetz, D., Hafner, G., Tiret, L., Meyer, J., & for the AtheroGene Investigators (2001) · Circulation · doi:10.1161/hc3701.095949 · Cited by 589 · cited 1×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundClinical effects and toxicity of interleukin-2 in patients with cancer
Lotze, M. T., Matory, Y. L., Rayner, A. A., Ettinghausen, S. E., Vetto, J. T., Seipp, C. A., & Rosenberg, S. A. (1986) · Cancer · doi:10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z · Cited by 355 · cited 1×
“It is also unknown whether the substantial toxicity associated with IL-2 administration (that limits its therapeutic usefulness) [ 6 ] is mediated through pathways common or distinct from those mediating its anti-cancer effects [7].”
BackgroundFactors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302 · cited 1×
“It has been observed that hematological toxicity induced by IL2 (thrombocytopenia and lymphopenia) is associated with increased frequency of clinical responses [8].”
BackgroundCotran, R. S., Pober, J. S., Gimbrone, M. A., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., & Lotze, M. T. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.6.1883 · Cited by 221 · cited 1×
“Although, it has been postulated that IL-2 acts through the in vivo expansion and activation of cytotoxic T lymphocytes [1] and/or the promotion of their migration within target tissues [3], it is likely that at the pharmacologic doses used therapeutically IL-2 has broader immune/pro-inflammatory effects [4,5].”
BackgroundPanelli, M. C., Wang, E., Phan, G., Puhlmann, M., Miller, L., Ohnmacht, G. A., Klein, H. G., & Marincola, F. M. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0035 · Cited by 196
Self-citationWhittington, R., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199346030-00009 · Cited by 176
Polymorphism in clinical immunology – From HLA typing to immunogenetic profiling
Jin, P., & Wang, E. (2003) · Journal of Translational Medicine · doi:10.1186/1479-5876-1-8 · Cited by 135
Self-citationInterleukin-2 in the treatment of renal cancer.
Margolin, K. A. (2000) · PubMed · Cited by 109
White, R. L., Schwartzentruber, D. J., Guleria, A. S., Macfarlane, M., White, D. E., Tucker, E. E., & Rosenberg, S. A. (1994) · Cancer · doi:10.1002/1097-0142(19941215)74:12<3135::aid-cncr2820741212>3.0.co;2-8 · Cited by 108
Self-citationWhite, R. L., Schwartzentruber, D. J., Guleria, A., Macfarlane, M. P., White, D. E., Tucker, E., & Rosenberg, S. A. (1994) · Cancer · doi:10.1002/1097-0142(19941215)74:12<3212::aid-cncr2820741221>3.0.co;2-i · Cited by 107 · cited 1×
“It is also unknown whether the substantial toxicity associated with IL-2 administration (that limits its therapeutic usefulness) [6] is mediated through pathways common or distinct from those mediating its anti-cancer effects [7].”
BackgroundSelf-citationMortarini, R., Borri, A., Tragni, G., Bersani, I., Vegetti, C., Bajetta, E., Pilotti, S., Cerundolo, V., & Anichini, A. (2000) · PubMed · Cited by 105
Kasid, A., Director, E. P., & Rosenberg, S. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.2.736 · Cited by 92 · cited 1×
“Although, it has been postulated that IL-2 acts through the in vivo expansion and activation of cytotoxic T lymphocytes [1] and/or the promotion of their migration within target tissues [3], it is likely that at the pharmacologic doses used therapeutically IL-2 has broader immune/pro-inflammatory effects [4,5].”
BackgroundPassive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
Fraker, D. L., Langstein, H. N., & Norton, J. A. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.1015 · Cited by 83 · cited 1×
“In addition, reversal of IL-2-induced toxicity by corticosteroid or anti-TNF-α antibodies blunts its therapeutic effects suggesting a proinflammatory nature for this association [9,10].”
BackgroundPorter, J. F., Shen, S., & Denhardt, D. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601533 · Cited by 82 · cited 1×
“It is also possible that TIMP1 at such high doses may increase cell proliferation and metabolic activity as previously reported [30].”
ResultBoccoli, G., Masciulli, R., Ruggeri, E. M., Carlini, P., Giannella, G., Montesoro, E., Mastroberardino, G., Isacchi, G., Testa, U., & Calabresi, F. (1990) · PubMed · Cited by 77
Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mulé, J. J., & Rosenberg, S. A. (1986) · PubMed · Cited by 67
Soluble adhesion molecule levels, neuropsychiatric Lupus and Lupus-related damage
Zaccagni, H. J. (2004) · Frontiers in bioscience · doi:10.2741/1273 · Cited by 52 · cited 1×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundTemporal variations of adhesion molecules and matrix metalloproteinases in the course of MS
Correale, J. D., & Molinas, M. D. L. M. B. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00204-2 · Cited by 52 · cited 2×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundList, J., Moser, R. P., Steuer, M. E., Loudon, W. G., Blacklock, J. B., & Grimm, E. A. (1992) · PubMed · Cited by 50
Deehan, D. J., Heys, S. D., Simpson, W., Herriot, R., Broom, J. I., & Eremin, O. (1994) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb07005.x · Cited by 48
Holmlund, A., Hulthe, J., Millgård, J., Sarabi, M., Kahan, T., & Lind, L. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00234-4 · Cited by 44 · cited 1×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundMaury, C. P. J., Liljeström, M., Laiho, K., Tiitinen, S., Kaarela, K., & Hurme, M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11294 · Cited by 37 · cited 1×
“Circulating levels of TNF-α and sTNFRI have been reported to be significantly increased in rheumatoid arthritis patients with amyloidosis as those without [31] (Figure 4) and after IL2 therapy [34] (Figure 5).”
BackgroundPanelli, M. C., Martin, B. M., Nagorsen, D., Wang, E., Smith, K., Monsurrò, V., & Marincola, F. M. (2004) · Cells Tissues Organs · doi:10.1159/000079986 · Cited by 31 · cited 2×
“This is a finding similar to what was previously noted in a small in vitro analysis of PBMC stimulated with IL-2 [15].”
BackgroundResultSelf-citationMechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression
Masztalerz, A., van Rooijen, N., Otter, W. D., & Everse, L. A. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0381-z · Cited by 28 · cited 1×
“In addition, the hypothesis that the direct or indirect effects of IL-2 in the target organ are mediated through mononuclear phagocyte activation is in line with the recently reported observation that macrophage activation by IL-2 is essential for tumor regression [14].”
ResultHajilooi, M., Sanati, A., Ahmadieh, A., Ghofraniha, A., & Massoud, A. M. (2003) · Immunological Investigations · doi:10.1081/imm-120025104 · Cited by 21 · cited 1×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundLieuw-a-Fa, M., Schalkwijk, C. G., & van Hinsbergh, V. W. M. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613407 · Cited by 15 · cited 1×
“The soluble form of adhesion molecules ICAM1, V-CAM, E selectin have been reported to be similarly elevated in the serum of chronic renal allograft rejection patients [22], multiple sclerosis and Lupus (([23,24], coronary artery disease [25,26], endothelial vasodilatation [27], immunotherapy of tumor patients with TNF…”
BackgroundLocker, G. J., Kofler, J., Stoiser, B., Wilfing, A., Wenzel, C., Woegerbauer, M., Steger, G. G., Zielinski, C. C., Mader, R. M., & Burgmann, H. (2000) · PubMed · Cited by 9
[Soluble cell adhesion molecules in chronic renal graft rejection].
Boratyńska, M. (1998) · PubMed · Cited by 3
Research works printed but not linked: 1
- Marincola FM Interleukin-2 Biol Ther Cancer Updates 1994 4 1 16
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
“The systemic administration of proinflammatory cytokines is often associated with severe offtarget toxicity, particularly flu-like symptoms, which may limit the dose and prevent the escalation of dosages needed for developing therapeutically effective regimens.(21) Similar to the ADC strategy, a strategy for using imm…”
BackgroundOpportunities and challenges in the diagnostic utility of dermal interstitial fluid
Friedel, M., Thompson, I. A. P., Kasting, G., Polsky, R., Cunningham, D., Soh, H. T., & Heikenfeld, J. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00998-9 · Cited by 360
Metadata
- Authors
- Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M.
- Affiliations
- National Institutes of Health (US)
- Carolinas Medical Center (US)
- Corresponding author
- Marincola, Francesco M
- Venue
- Journal of Translational Medicine
- Published
- 2004-06-02
- Volume
- 2
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC434535
- OpenAlex
- W2131055846
- Cited by
- 139
- References
- 33
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 3 · 2016: 2 · 2015: 3 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Translational Medicine (publishedVersion)
- PubMed Central (publishedVersion, other-oa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- interleukin-2, cytokine storm, renal cell carcinoma, cytokine kinetics, mononuclear phagocytes, tumor microenvironment, T cell activation, cytokine toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.